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Objective: To prospectively determine whether diffusion basis spectrum imaging (DBSI) detects, differentiates and
quantitates coexisting inflammation, demyelination, axonal injury and axon loss in mice with optic neuritis (ON)
due to experimental autoimmune encephalomyelitis (EAE), and to determine if DBSI accurately measures effects
of fingolimod on underlying pathology.
Methods: EAE was induced in 7-week-old C57BL/6 female mice. Visual acuity (VA) was assessed daily to detect
onset of ON after which daily oral-treatment with either fingolimod (1 mg/kg) or saline was given for ten weeks.
In vivo DBSI scans of optic nerves were performed at baseline, 2-, 6- and 10-weeks post treatment. DBSI-derived
metrics including restricted isotropic diffusion tensor fraction (putatively reflecting cellularity), non-restricted
isotropic diffusion tensor fraction (putatively reflecting vasogenic edema), DBSI-derived axonal volume, axial
diffusivity, λ‖ (putatively reflecting axonal integrity), and increased radial diffusivity, λ⊥ (putatively reflecting
demyelination). Mice were killed immediately after the last DBSI scan for immunohistochemical assessment.
Results: Optic nerves of fingolimod-treated mice exhibited significantly better (p < 0.05) VA than saline-treated
group at each time point. During ten-week of treatment, DBSI-derived non-restricted and restricted-isotropicdiffusion-tensor fractions, and axonal volumes were not significantly different (p > 0.05) from the baseline
values in fingolimod-treated mice. Transient DBSI-λ‖ decrease and DBSI-λ⊥ increase were detected during Fin
golimod treatment. DBSI-derived metrics assessed in vivo significantly correlated (p < 0.05) with the corre
sponding histological markers.
Conclusion: DBSI was used to assess changes of the underlying optic nerve pathologies in EAE mice with ON,
exhibiting great potential as a noninvasive outcome measure for monitoring disease progression and therapeutic
efficacy for MS.

1. Introduction
Multiple sclerosis (MS) is an immune-mediated inflammatory
demyelinating disease of central nervous system (CNS). Irreversible
axonal injury and axon loss are believed to be major causes of permanent
neurologic impairments in MS (Rahim et al., 2018; Sun et al., 2020).

Although early intervention with disease-modifying therapy (DMT) has
been shown to decrease the relapse rate and slow short-term disability
progression in MS patients (Montalban et al., 2018), it is still uncertain
whether it is associated with a lower long-term risk of disability
(Kavaliunas et al., 2017; Torkildsen et al., 2016). To address this issue,
robust markers which can precisely capture and discriminate axonal loss
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from other underlying pathologies, such as inflammation and demye
lination, and monitor intervention response are urgently needed to help
clinicians make more efficient personalized management decision for
MS patients and to assess responses to treatments.
Optic neuritis (ON) is a frequent manifestation of MS, and is also
frequently encountered on its own, or as part of other diseases such as
neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody
disease. Conventional T2-weighted imaging, T1-weighted gadolinium
contrast enhanced imaging, magnetization transfer imaging (MTI), and
diffusion tensor imaging (DTI) have been widely applied on the evalu
ation of optic nerve in MS-related ON (Hickman et al., 2004, 2005;
Jackson et al., 1998; Naismith et al., 2012a; Rocca and Filippi, 2007). In
addition, optic nerve damages in patients with MS have been commonly
assessed based on optical coherence tomography (OCT) measured
retinal nerve fiber layer thickness change (Gajamange et al., 2018).
A lack of pathological specificity of these imaging modalities has
contributed to discrepancies between neuroimaging findings and clin
ical outcomes, commonly known as the clinicoradiological paradox
(Barkhof, 2002; Costello et al., 2006; Davis, 2014), resulting in part from
the heterogeneous nature of MS in clinical course and underlying pa
thologies (Leray et al., 2010; Scalfari et al., 2010). We have developed
diffusion basis spectrum imaging (DBSI) and demonstrated its ability to
detect and differentiate inflammation, axonal injury, axon loss and
demyelination in mice with experimental autoimmune encephalomy
elitis (EAE), and autopsied and biopsied specimens from MS patients
(Lin et al., 2017; Shirani et al., 2019; Sun et al., 2020; Wang et al., 2014,
2015, 2011; Ye et al., 2020).
Therefore, we hypothesized that DBSI, which is pathologically more
specific than standard MRI, would be able to assess the efficacy of fin
golimod (also known as FTY720, Selleck Chemicals LLC,) treatment of
ON through longitudinally quantifying the evolution of several coex
isting optic nerve pathologies using a preclinical EAE mouse model
which has ON.

2. Materials and Methods
2.1. Animal model
Procedures were approved by Washington University Institutional
Animal Care and Use Committee. Female C57BL/6 mice at 7 weeks of
age were obtained from Jackson Laboratory (Bar Harbor, ME).
2.2. Induction of EAE and visual acuity (VA) measurements in mice
Before immunization, 6-week old C57BL/6 mice were housed under
humidity and temperature-controlled conditions with 12-hour dark/
light cycle for two weeks. Mice then underwent baseline DBSI of optic
nerves, followed acclimation in the facility for another 10–14 days
before active immunization with myelin oligodendrocyte glycoprotein
peptide (MOG35-55). Immunization was performed over two sites on the
flanks with the antigen emulsified in incomplete Freund’s adjuvant
(IFA), followed by intravenous injections of 200 ng Pertussis toxin (List
Laboratories, Campbell CA) on days 0 and 2. Sham-EAE was prepared on
naïve mice with injection of IFA without antigen followed by 200 ng of
Pertussis toxin on days 0 and 2 (Fig. 1A).
The VA of mice was measured as previous described using the Virtual
Optomotry System (Optomotry, Cerebral Mechanics, Inc.). Before im
munization, normal VA was confirmed for each eye (VA = 0.34 ± 0.04c/
d, n = 34 eyes from 17 mice) at baseline. After immunization, blinded
VA measurement was performed daily before the onset of ON (9–22 days
post-immunization) which was defined as VA ≤ 0.25c/d in our previous
study (Chiang et al., 2014; Lin et al., 2017, 2014, 2020), and then
weekly till the end of the study (Fig. 1B).
2.3. Fingolimod treatment
Starting on the first day of onset of ON, mice were alternately
assigned to either receive daily gavage of fingolimod (n = 9 mice, 1 mg/

Fig. 1. Diagram shows experimental design and visual acuity measurement through the entire experiment. (A) DBSI was performed at two weeks prior to active
immunization (as baseline), 2, 6, and 10 weeks after treatment started. Treatment commenced if one eye visual acuity (VA) ≤ 0.25cycle/degree (c/d). Red-dashed
line indicates the cut-off VA of 0.25c/d. Daily gavage of either Fingolimod (1 mg/kg) or the equal volume of saline was administrated for 10 weeks. (B) Daily VA was
performed at the first two weeks after immunization followed by weekly VA from 3 to 10 weeks. Comparing to VA of saline-treated eyes, VA was significant higher in
Fingolimod-treated eyes from Day 3 to ten-week treatment (p < 0.05). ⋆ indicates p < 0.05, comparing to corresponding saline group. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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kg, Cat No. S5002, Selleck Chemicals LLC) or the same volume of saline
(n = 9 mice) for 10 consecutive weeks. Mice were alternately assigned to
receive fingolimod or saline until the 9th pair. The final number in
fingolimod- and saline-treated group was 8 and 9 EAE mice, respectively
due to the lack of VA impairment or clinical signs during the course of
assessment of the last EAE mouse assigned to fingolimod treatment.

the parametric maps to calculate the mean value for individual DBSI
metrics. A separate ROI encompassing the whole optic nerve was drawn
on cross-sectional images obtained with diffusion weighting gradient
direction orthogonal to optic nerve (larger than the ROIs for other DBSI
metrics). The ROI included the edge voxel of optic nerve. DBSI-derived
fiber volume was calculated from the optic nerve volume (the entire ROI
on DWI) multiplied by the corresponding DBSI fiber fraction. The dilu
tion effect of inflammation and surrounding CSF is considered in the
fiber volume computation in the manner (Lin et al., 2020).

2.4. In vivo diffusion basis spectrum imaging (DBSI)
In vivo DBSI was performed two weeks before immunization (base
line DBSI), and then at two, six and ten weeks after initiation of fingo
limod treatment. DBSI were performed on a 4.7-T small-animal MRI
scanner (Agilent/Varian) equipped with an Agilent/Magnex HD imag
ing gradient coil (Magnex/Agilent). Mice were anesthetized with iso
flurane/O2 [2% (vol/vol) for induction followed by 0.7–0.8% for
maintenance] throughout the imaging experiment. Body temperature
was maintained at 37 ◦ C with a circulating warm water pad. A diffusion
weighted mid-sagittal image was acquired to localize mouse optic
nerves, followed by an oblique image plan perpendicular to the optic
nerve to obtain the final image view using a multi-echo spin-echo
diffusion-weighting sequence (Tu et al., 2014). The final diffusionweighted MRI for DBSI analysis employed a 25-direction diffusionencoding scheme adding an extra b = 0 data as previously reported
(Chiang et al., 2014) with the following acquisition parameters: TR =
1500 ms, TE = 35 ms, NE = 2, inter-echo delay = 20.7 ms, FOV = 22.5 ×
22.5 mm2, matrix size = 192 × 192 (zero-filled to 384 × 384), slice
thickness = 0.8 mm, maximal b-value = 2,200 s/mm2, total scan time =
2 hr. 4 min.

2.7. Histology analysis
After the last DBSI scan, mice were killed and the optic nerves were
collected and embedded in 2% agar gel (Blewitt et al., 1982), followed
by paraffin embedding of the agar block. The paraffin blocks were cut in
the axial plane at a thickness of 5-µm for immunohistochemistry (IHC)
staining, including SMI-31, SMI-312, MBP, and DAPI. The whole field of
SMI-31, MBP, and DAPI stained images at 100 × magnification with oil
lens was captured with the same fluorescence light intensity and expo
sure time for each image. All captured images were converted to 8-bit
gray scale and analyzed using threshold, edge enhancement, analyze
particles and gray level watershed segmentation functions in ImageJ
(https://imagej.nih.gov/ij/, NIH, US). Nucleus counts were performed
by signal intensity threshold on DAPI staining (Lin et al., 2017, 2020).
2.8. Statistical analysis
Data were presented as mean ± standard deviation. VA and MRI
measurements were performed on each eye at baseline, end of two-, sixand ten-week treatment. Data were analyzed with a mixed random ef
fects repeated measures model with side, time, treatment, and time by
treatment interaction as fixed effects. Mouse within treatment was a
random effect. Correlation of repeated-measures was estimated in a firstorder auto-regressive covariance structure. Variance components were
estimated by group to account for differences in variance. Regression of
MRI measurements on histology measures were performed with mixed
random effect regression to account for two eyes measured for each
mouse.

2.5. Imaging analysis
Data was processed with DBSI multi-tensor analysis packages
developed in-house with Matlab. (Wang et al., 2015, 2011). The imaging
data were modeled according to Equation 1:
N
Aniso
∑

Sk =

⇀

⇀
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The quantities Sk and ⃒bk ⃒ are the signal and b-value of the kth

3. Results

diffusion gradient, NAniso is the number of anisotropic tensors (fiber
tracts), Ψik is the angle between the kth diffusion gradient and the
principal direction of the ith anisotropic tensor, λ||i and λ⊥i are the axial
and radial diffusivity of the ith anisotropic tensor, fi is the signal intensity
fraction for the ith anisotropic tensor, and a and b are the low and high
diffusivity limits for the isotropic diffusion spectrum (reflecting cellu
larity and edema) f(D). For a coherent fiber bundle like the optic nerve,
NAniso = 1. DBSI derived fi represents the density of axons derived from
retinal ganglion cells (fiber fraction) in the image voxel, taking into
account of intra-voxel pathological and structural complications. Based
on prior work, DBSI derived λ|| and λ⊥ reflect axon and myelin integrity
respectively: ↓ λ|| = axonal injury and ↑ λ⊥ = demyelination. Our pre
vious experimental findings suggest that the restricted isotropic diffu
sion fraction reflecting cellularity can be derived by the summation of
f(D) at 0 ≤ ADC ≤ 0.6 μm2/ms. The summation of the remaining f(D) at
ADC > 0.6 μm2/ms represents “non-restricted” isotropic diffusion,
which denotes regions of tissue loss, increased inter-axonal space,
vasogenic edema and CSF.

3.1. Visual acuity (VA) in fingolimod-treated mice was better than that in
saline-treated mice
There was no VA difference between fingolimod-treated (0.34 ±
0.03c/d, n = 16 eyes, from 8 EAE mice) and saline-treated groups (0.36
± 0.04c/d, n = 18 eyes, from 9 EAE mice) at baseline before treatment.
Over the treatment period, the VA of fingolimod-treated mice was
significantly better than saline-treated mice from 3 days to 10 weeks
after treatment onset (p < 0.05, Fig. 1B).
3.2. DBSI detected the reduced inflammation in fingolimod-treated optic
nerves
Representative DBSI non-restricted isotropic fraction (putatively
reflecting vasogenic edema) and restricted isotropic fraction (putatively
reflecting cellularity) maps of optic nerves were presented to demon
strate the evolution of these markers at baseline (before immunization),
2, 6, and 10 weeks after treatment (Fig. 2A).
In the group of saline-treated mice with ON, non-restricted isotropic
fraction of optic nerves significantly increased from baseline by 133% (p
= 0.020), 198% (p = 0.001), and 229% (p < 0.001) at 2, 6, and 10 weeks
after treatment, respectively (Fig. 2B). Restricted isotropic fraction of
optic nerves significantly increased from the baseline by 201% (p <
0.001), 98% (p = 0.070), and 164% (p = 0.002) at 2, 6, and 10 weeks
after placebo treatment, respectively (Fig. 2C). In the fingolimod

2.6. Regions of interest (ROI)
ROIs were manually drawn with ImageJ (https://imagej.nih.gov/ij/,
NIH, US) at the center of each optic nerve on the diffusion-weighted
image (the edge voxel of optic nerve were avoided), which corre
sponded to the diffusion gradient direction perpendicular to optic
nerves, to minimize partial volume effects. ROIs were then transferred to
3
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Fig. 2. DBSI-derived non-restricted fraction
(putative edema) and restricted (putative
cellularity) isotropic tensor fraction maps for
representative saline- and fingolimod-treated
optic nerves from baseline to 10-week treat
ment (A). Comparing to baseline, fingolimod
effectively suppressed putative inflammation
markers, including non-restricted and
restricted fractions, after treatment (p <
0.05, B and C). However, significant increase
in saline-treated optic nerves from baseline
was shown in non-restricted fraction at all
time points (p < 0.05) and in restricted
fraction at 2 and 10 (both p < 0.05) but not
at 6 (p = 0.06) weeks (B and C). Comparing
to saline, significantly reduced non-restricted
fraction at 6 and 10 weeks (p < 0.05) in
fingolimod-treated optic nerves (B). Mild but
not significant reduced restricted fraction
was shown in fingolimod-treated optic nerve
all the time (C). ⋆ indicates p < 0.05,
comparing between saline and fingolimod
groups $ indicates p < 0.05, comparing to its
baseline within group.

treatment group, non-restricted isotropic fraction increased from base
line by 21% (p = 0.740), 48% (p = 0.440), and 63% (p = 0.320) at 2, 6,
and 10 weeks after treatment (Fig. 2B), while restricted isotropic frac
tion increased from baseline by 72% (p = 0.180), 28% (p = 0.590), and
51% (p = 0.340) at 2, 6, and 10 weeks (Fig. 2C).
In comparison to the saline-treated group, the fingolimod-treated
mice exhibited significantly lower non-restricted isotropic fraction at 2
(60% lower, p = 0.070), 6 (62% lower, p = 0.020) and 10 weeks (63%
lower, p = 0.010) after treatment (Fig. 2B). Although the increase in
restricted isotropic fraction was numerically greater for the placebo
group, differences between the two treatment groups were not statisti
cally significant.

3.3. DBSI detected reduced axon loss in fingolimod-treated optic nerves
Representative fiber fraction (the total diffusion signal from aniso
tropic axonal fiber bundles) maps of optic nerves at baseline, 2, 6, and
10 weeks after treatment were presented to demonstrate the evolution of
fiber fraction (Fig. 3A).
In the saline-treated group, DBSI fiber fraction (putative marker of
apparent axonal density) of the optic nerves decreased by 10% (p =
0.140), 24% (p = 0.002) and 25% (p = 0.003) at 2, 6, and 10 weeks,
respectively, when compared to baseline before immunization (Fig. 3B).
DWI-derived volumes of optic nerves decreased by 23% (p = 0.004),
37% (p < 0.001) and 25% (p = 0.002) at 2, 6, and 10 weeks, respec
tively, from baseline before immunization (Fig. 3C). DBSI-derived
axonal volume (putative marker of axonal content) decreased by 28%
Fig. 3. DBSI-derived fiber fraction reflects
total signal from anisotropic diffusion tensor
components, reflecting axonal fiber density
(A, B). Comparing to baseline, significantly
decreased fiber fraction was detected at each
time point in saline-treated group (p < 0.05)
but not in fingolimod-treated optic nerves at
all time points (B). Significantly reduced
DWI-derived nerve volume was seen in
saline-treated optic nerves (p < 0.05) but not
in fingolimod-treated group from baseline to
the rest of time points (C). To remove the
confounding effects from inflammation,
DBSI-derived axonal volume (D) was
computed multiplying fiber fraction (B) by
DWI-derived nerve volume (C) in each indi
vidual optic nerve. Comparing to baseline,
significantly reduced DBSI-derived axonal
volume was shown in saline-treated optic
nerves (p < 0.05) but not in fingolimodtreated optic nerves at all time points (D).
Comparing to saline group, fingolimodtreated optic nerves showed significantly
higher axon volume at all time points (D),
suggesting axonal prevention with fingoli
mod treatment. ⋆ indicates p < 0.05,
comparing between saline and fingolimod

groups $ indicates p < 0.05, comparing to its baseline within group.
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(p = 0.006), 45% (p < 0.001), and 36% (p < 0.001) at 2, 6, and 10
weeks, respectively, when compared to baseline before immunization
(Fig. 3D). In the fingolimod-treated group, no significant difference from
baseline was observed for DBSI fiber fraction, DWI-derived optic nerve
volume, or DBSI axonal volume at any time point after treatment.
Compared to saline-treated mice, the fingolimod-treated group
exhibited significantly higher DBSI fiber fraction at 6 weeks (38%
higher, p = 0.020) and 10 weeks (Fig. 3B, 33% higher, p = 0.030), with
significantly lower DWI-derived optic nerve volumes at 6 weeks (35%
higher, p = 0.02) and at 10 weeks (39% higher, p = 0.005, Fig. 3C).
DBSI-derived axonal volumes in the fingolimod-treated optic nerves
were higher than for saline-treated optic nerves at 2 weeks (25% higher,
p = 0.400), 6 weeks (62% higher, p = 0.020) and 10 weeks (64% higher,
p = 0.007) after treatment commencement (Fig. 3D).

apparent optic nerve sizes of saline-treated group were smaller than
those of fingolimod-treated group (Fig. 5A–I). However, compared to
one representative wildtype (WT) optic nerves (10-week-old C57BL/6
female mouse optic nerve), fingolimod-treated group showed enlarged
staining spots (Fig. 5b, e, h; blue arrows), suggesting swollen axons or
myelin debris aggregation. Moreover, increased positive DAPI staining
areas (cell nuclei) were also seen in both saline and fingolimod treat
ment groups compared to WT optic nerve, suggesting increased cellu
larity (Fig. 5J and K).
DBSI λ‖, DBSI λ⊥, DBSI-derived axon volume, and DBSI restricted/
non-restricted fractions correlated well with SMI-31 area fraction
(Fig. 6A), MBP area fraction (Fig. 6B), SMI-312 area fraction (Fig. 6C)
and DAPI density (Fig. 6D/E), respectively in the ON-affected optic
nerves.

3.4. DBSI detection of diminished injury to residual axons in fingolimodtreated optic nerves

4. Discussion
Understanding of the evolution of chronic human CNS diseases over
time and response to therapies has been hindered by inability to access
CNS specimens to examine longitudinally. In this study, we hypothe
sized that DBSI is capable to assess the efficacy of fingolimod treatment
in an animal model of ON. The optic nerve was chosen for examination
because it is a frequent site of inflammatory demyelination in MS and
related diseases. Moreover, the volume of the optic nerve can be
measured, allowing precise measurement of axonal content, even in the
presence of inflammation and edema. Previously, DTI has played a
significant role to noninvasively identify axonal injury and demyeli
naiton in MS subjects (Kuchling et al., 2017; Naismith et al., 2009,
2012b; Smith et al., 2011) or its animal models (Sun et al., 2007).
However, single-tensor DTI-determined axonal injury or demyelination
may be confounded by coexisting inflammation limiting its ability to
accurately assess the severity of axonal loss, a hallmark pathology of
disease progression. DBSI is a data-driven approach modeling diffusionweighted MRI signals as a linear combination of multiple anisotropic
and isotropic tensors to resolve the underlying structural and patho
logical complexity. Thus, DBSI noninvasively quantifies coexisting pa
thologies over time and quantitatively assesses axonal loss in fingolimod
(an FDA-approved oral medication for MS) or saline-treated optic
nerves.
Optic neuritis, a common occurrence in people with MS, can lead to
irreversible visual impairment (Galetta et al., 2015). Fingolimod is
approved for patients with RRMS. However, its neuroprotective effects
remain uncertain (Ambrosius et al., 2017). Rau et al. reported apoptotic

Fig. 4A shows representative DBSI axial diffusivity (λ‖) and radial
diffusivity (λ⊥) maps at baseline, 2, 6, and 10 weeks after treatment for
each group. Compared to baseline, for saline-treated mice DBSI λ‖
significantly decreased by 17% (p < 0.001), 14% (p < 0.001), and 12%
(p = 0.001) at 2, 6, and 10 weeks (Fig. 4B), while DBSI λ⊥ significantly
increased by 45% (p = 0.015), 62% (p = 0.001) and 75% (p < 0.001) at
2, 6, and 10 weeks (Fig. 4C), respectively. In the fingolimod treatment
group, DBSI λ‖ decreased by 7% (p = 0.040), 7% (p = 0.033), 3% (p =
0.330) at 2, 6, 10 weeks (Fig. 4B), while DBSI λ⊥ increased from baseline
by 14% (p = 0.400), 15% (p = 0.400) and 9% (p = 0.600) at 2, 6 and 10
weeks after treatment (Fig. 4C).
Compared the difference between groups (saline vs. fingolimod),
fingolimod-treated group showed no significant differences on DBSI λ‖
for all the time points while DBSI λ⊥ decreased by 38% at 10 weeks (p =
0.010, Fig. 4C).
3.5. Immunohistochemistry (IHC) staining of optic nerves
Mice were euthanized at the end of the treatment period for histo
logic assessment of the optic nerves. IHC staining of total neurofilaments
(SMI-312, stains both injured and intact axons), phosphorylated neu
rofilaments (SMI-31, stains intact axons), and myelin basic protein
(MBP, stains myelin) revealed that the saline-treated group exhibited
less staining for SMI-312 (Fig. 5A), MBP (Fig. 5D), and SMI-31 (Fig. 5G),
when compared to fingolimod-treated group (Fig. 5B, E, H). The

Fig. 4. DBSI-derived axial (λ‖) and radial
(λ⊥) diffusivity maps of representative salineand fingolimod-treated optic nerves from
baseline to 10-week treatment (A) were
derived from anisotropic diffusion tensor
components. Comparing to baseline, signifi
cantly decreased DBSI-λ‖ was detected at all
time points in saline-treated optic nerves (B,
p < 0.05). In contrast, decreased DBSI- λ‖
was only seen at 2 and 6 weeks in
fingolimod-treated optic nerves (B, p <
0.05). Significantly increased DBSI-λ⊥ was
detected in saline-treated (p < 0.05) but not
in fingolimod-treated optic nerves at all time
points (C). The results showed intermittent
axonal injury during fingolimod treatment.
After 10-week fingolimod treatment, DBSI-λ‖
and DBSI-λ⊥ were not different from their
baseline values (B, C). ⋆ indicates p < 0.05,
comparing between saline and fingolimod
groups $ indicates p < 0.05, comparing to its
baseline within group.

5

R. Yang et al.

NeuroImage: Clinical 31 (2021) 102732

Fig. 5. Representative 100 × immunohisto
chemical staining images of total neurofila
ment (SMI-312, staining both injured and
intact axons, A–C), myelin basic protein
(MBP, assessing myelin, D–E), phosphory
lated neurofilament (SMI-31, reflecting
intact axons, G–I), and 4′ , 6-dianidino-2-phe
nylindole (DAPI, detecting nuclei, J – L) from
saline-, and fingolimod-treated optic nerves
at 10 weeks after treatment. Comparing to
wild-type (WT) optic nerves, saline-treated
optic nerves showed lowest staining in
tensity in SMI-312 (A), MBP (D), and SMI-31
(G), suggesting axonal loss, demyelination,
and axonal injury, respectively. In contrst,
moderate lower staining intensity in SMI-312
(B), MBP (E), and SMI-31(H), suggesting
mild axon and myelin injury were assessed in
fingolimod-treated optic nerves. Blue arrows
indicated swelling axon and myelin. Stron
gest DAPI stains in saline-treated optic nerve
(J) suggested highest cellularity than
fingolimod-treated (K) and wild-type (L) optic nerves.White scale bar: 50 μm Yellow scale bar: 10 μm. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Fig. 6. Mixed random-effect regression
analysis for the correlation between DBSI
parameters and IHC biomarkers. SMI-31
counts and MBP area fraction (the ratio of
positive staining counts and total tissue
area), SMI-312 area (absolute value of posi
tive staining counts), and DAPI counts were
statistically significant associated with DBSIλ‖ (A), DBSI-λ⊥ (B), DBSI-derived axonal
volume (C), DBSI restricted isotropic fraction
(D), and DBSI non-restricted isotropic frac
tion (E), suggesting that in vivo DBSI quan
titatively
reflected
the
complicated
pathologies including axonal injury, demye
lination, axonal loss, and cell infiltration.

cell death of retinal ganglion cells in rats with EAE that were treated
with fingolimod, although axonal preservation in optic nerves was seen
by histological data (Rau et al., 2011). An et al. reported axonal pres
ervation in optic nerves by histological validation and moderate visual
dysfunction (better than non-treated EAE mice but worse than naïve

control mice) by optometry (An et al., 2013). However, both studies
could only rely upon end-point histological results at the conclusion of
study to evaluate whether fingolimod is axonal protective. In the current
study, DBSI detected improved transient inflammation (via the putative
inflammatory markers: restricted fraction → inflammatory cellularity
6
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and non-restricted fraction → vasogenic edema) and axonal pathologies
(via putative DBSI axonal injury and loss markers) in fingolimod-treated
optic nerves. Results suggest axonal protection of fingolimod could be
secondary to reduced inflammation.
We observed that daily oral fingolimod markedly reduced inflam
mation, evidenced by the decrease in DBSI restricted isotropic fraction
(reflecting cellular inflammation) and non-restricted isotropic fraction
(reflecting vasogenic edema), in accordance with the action of fingoli
mod to sequester lymphocytes in secondary lymphoid tissue and thus
inhibit lymphocytes from entering the CNS (Zhang et al., 2015b).
Additionally, we also observed that both decreased λ|| (putative axonal
injury, Fig. 4B) and increased λ⊥ (putative demyelination, Fig. 4C) were
significantly improved in mice treated with fingolimod versus those
treated with saline. Mice were euthanized and optic nerves were
examined histologically at the conclusion of 10-week treatment. As
previously reported (Lin et al., 2017, 2020) DBSI longitudinally moni
tored disease progression. After 10 weeks of fingolimod therapy,
reduced inflammation, less demyelination, and diminished axonal
injury of optic nerves was confirmed by IHC, suggesting DBSI is capable
of detecting long-term anti-inflammatory and neuroprotective effects
with fingolimod treatment. The histological findings were consistent
with DBSI-derived putative imaging biomarkers of optic nerve pathol
ogies. Following increased λ⊥ (demyelination) in optic nerves of EAE
mice with ON, we noted the subsequent reduction of DBSI λ⊥ after 10
weeks of fingolimod but not placebo treatment, suggesting remyelina
tion could have occurred in those mice treated with fingolimod. There is
no direct histological data to validate in this study, but the profile of
DBSI-derived λ⊥ was consistent with other reports (Yazdi et al., 2020;
Zhang et al., 2015a).
Limitations of the current study include that we performed histo
logical validation at the last time point, 10 weeks after treatment
commenced. Definitive demonstration of the evolution of the underlying
optic nerve pathologies may require further cross-sectional histological
validation studies. Second, this proof-of-concept study may be limited
due to the small sample size (17 mice divided between fingolimod and
saline treatment groups). Although each mouse was imaged 4 times,
generating 68 imaging datasets thus increasing the power of the study,
the limitation of small number of animals studied needs to be kept in
mind when drawing a conclusion. Third, visual function is not specific to
optic nerve pathologies since EAE (and MS) can affect other parts of the
visual system, such as retinal ganglion cells (Shindler et al., 2006).
Damage in regions other than the optic nerves was not taken into
consideration in the present study. Finally, not all DBSI pathologic
metrics have corresponding IHC markers. For example, non-restricted
fraction is a putative marker of vasogenic edema in vivo, associated
with inflammation in EAE. However, postmortem histology is not suit
able for validating this metric due to fixation and paraffin embedding for
IHC analysis although indirect evidence does support that non-restricted
fraction is associated with inflammation (Fig. 6E, correlation between
non-restricted fraction and DAPI).
In conclusion, our preclinical study demonstrates that DBSI-based
biomarkers reflect underlying pathologic changes and, importantly,
therapeutic efficacy of an established treatment. Moreover, the results
strongly suggest that DBSI can detect and quantitate remyelination
following demyelination. These data support that DBSI, a noninvasive
contrast agent-free MR technique, offers new possibilities for precise
clinical diagnosis as well as assessing disease evolution and treatment
responses in CNS inflammatory demyelinating diseases, such as MS.
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